Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life ...

New documents have investigators questioning inconsistencies and omissions in data reporting in the PLATO trial, building on ...

Researchers examined pooled data from two clinical trials that enrolled patients with low- or intermediate-grade ductal ...

SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...

AstraZeneca PLC AZN shares inched down 0.95% to £104.68 Friday, on what proved to be an all-around grim trading session for ...

The AstraZeneca PLC ADR AZN dropped 0.54% to $66.58 Friday, on what proved to be an all-around mixed trading session for the ...

Action is the latest following Baldwin’s investigation into the extremely high prices these companies charge for inhalers ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

AstraZeneca is proud to announce the successful conclusion of its inaugural Week of Service, which took place across the ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...